AngioDynamics, Inc. (NASDAQ:ANGO) Given Average Rating of “Hold” by Brokerages

Shares of AngioDynamics, Inc. (NASDAQ:ANGO) have received an average rating of “Hold” from the five ratings firms that are currently covering the stock, Marketbeat.com reports. Two research analysts have rated the stock with a sell recommendation, two have given a buy recommendation and one has issued a strong buy recommendation on the company. The average 12-month target price among brokerages that have updated their coverage on the stock in the last year is $19.50.

A number of brokerages have issued reports on ANGO. HC Wainwright boosted their target price on shares of AngioDynamics from $16.00 to $19.00 and gave the company a “buy” rating in a report on Wednesday, July 15th. Canaccord Genuity Group lifted their price target on AngioDynamics from $16.00 to $20.00 and gave the company a “buy” rating in a research report on Wednesday, July 15th. Freedom Capital upgraded AngioDynamics to a “strong-buy” rating in a research note on Monday, April 6th. Weiss Ratings reissued a “sell (d-)” rating on shares of AngioDynamics in a report on Friday, July 17th. Finally, Zacks Research downgraded AngioDynamics from a “hold” rating to a “strong sell” rating in a research note on Thursday, July 16th.

AngioDynamics Stock Up 0.1%

Shares of NASDAQ:ANGO opened at $14.79 on Friday. The firm has a market capitalization of $611.27 million, a PE ratio of -17.00 and a beta of 0.34. AngioDynamics has a twelve month low of $8.36 and a twelve month high of $15.19. The company has a 50-day moving average price of $12.81 and a two-hundred day moving average price of $11.50.

AngioDynamics (NASDAQ:ANGO) last posted its quarterly earnings results on Tuesday, July 14th. The medical instruments supplier reported ($0.07) earnings per share (EPS) for the quarter, beating the consensus estimate of ($0.11) by $0.04. The company had revenue of $86.61 million for the quarter, compared to analyst estimates of $80.24 million. AngioDynamics had a negative net margin of 11.48% and a negative return on equity of 5.73%. AngioDynamics has set its FY 2027 guidance at -0.290–0.240 EPS. Analysts anticipate that AngioDynamics will post -0.27 earnings per share for the current fiscal year.

Insider Activity at AngioDynamics

In other news, SVP Warren Nighan, Jr. sold 23,370 shares of the firm’s stock in a transaction that occurred on Thursday, July 30th. The shares were sold at an average price of $14.72, for a total value of $344,006.40. Following the completion of the transaction, the senior vice president directly owned 64,745 shares in the company, valued at approximately $953,046.40. This trade represents a 26.52% decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through the SEC website. Company insiders own 6.00% of the company’s stock.

Institutional Trading of AngioDynamics

Several institutional investors and hedge funds have recently bought and sold shares of ANGO. Franklin Resources Inc. increased its holdings in shares of AngioDynamics by 2.3% in the fourth quarter. Franklin Resources Inc. now owns 48,359 shares of the medical instruments supplier’s stock worth $621,000 after purchasing an additional 1,076 shares during the period. Farther Finance Advisors LLC boosted its stake in AngioDynamics by 146.4% during the fourth quarter. Farther Finance Advisors LLC now owns 2,018 shares of the medical instruments supplier’s stock valued at $26,000 after buying an additional 1,199 shares during the period. Deutsche Bank AG boosted its stake in AngioDynamics by 5.9% during the fourth quarter. Deutsche Bank AG now owns 35,584 shares of the medical instruments supplier’s stock valued at $457,000 after buying an additional 1,992 shares during the period. Kemnay Advisory Services Inc. bought a new stake in AngioDynamics during the fourth quarter valued at $27,000. Finally, Price T Rowe Associates Inc. MD grew its position in AngioDynamics by 5.4% during the fourth quarter. Price T Rowe Associates Inc. MD now owns 44,298 shares of the medical instruments supplier’s stock worth $569,000 after buying an additional 2,263 shares in the last quarter. 89.43% of the stock is currently owned by hedge funds and other institutional investors.

About AngioDynamics

AngioDynamics, Inc is a medical technology company headquartered in Latham, New York, that develops, manufactures and markets a broad range of minimally invasive medical devices. The company’s products focus on three core areas: vascular access, peripheral vascular intervention and interventional oncology. Its solutions are designed to improve procedural outcomes, reduce complications and enhance patient comfort in hospital and outpatient settings.

In the vascular access segment, AngioDynamics offers a portfolio of devices including implanted ports, peripherally inserted central catheters (PICCs), hemodialysis catheters and specialty blood management products.